On Wednesday 17 July, NHS England published their May 2019 Prioritisation Decisions and approved allogeneic haematopoietic stem cell transplants for Primary Immunodeficiencies (PID).
Previously, allogeneic haematopoietic stem cell transplants for PID have only been available for children and have been made available for adult patients since early 2018 on a temporary basis whilst this review was undertaken.
This latest decision has created clear criteria for patients of all ages with PIDs to access this treatment if medically appropriate. For some patients, Primary Immunodeficiencies can be life-threatening and for others, means life-long management and prevention of harmful symptoms and side effects.
Welcoming the commitment by NHS England, Henny Braund, Chief Executive at Anthony Nolan said: “We’re pleased to see the lifesaving potential of stem cell transplants being offered to more patient groups who would benefit from a donor graft, and the improved quality of life they would experience.
“PIDs can significantly reduce patients’ quality of life and can be life-threatening to a small number.
“For those who are living with life-long management therapies, an allogeneic transplant is a chance to restore their health and reduce the risk of developing infections later in life, preventing irreversible harm. Allogeneic transplants could also save the lives of some adults patients where current treatments are palliative only.
“This is a welcome change for patients with PIDs, which could save more lives, and improve their quality of life. We’re looking forward to working closely with NHS England to make further strides in this area.”